Clinical Features and Disease Course of Cancer Patients Infected with SARS-CoV-2 During Anticancer Treatments
| العنوان: | Clinical Features and Disease Course of Cancer Patients Infected with SARS-CoV-2 During Anticancer Treatments |
|---|---|
| المؤلفون: | Aleksandra Babic, Sofija Milanovic, Sanja Milenković, Zlata Hufnagel, Sara Filipović, Nikola Borlja, Nenad Miladinovic, Jelena Dobrić, Marina Stojanović, Jelena Milin-Lazović, Aleksandar Gavrić |
| المصدر: | Serbian Journal of Experimental and Clinical Research. |
| بيانات النشر: | Walter de Gruyter GmbH, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Oncology, medicine.medical_specialty, business.industry, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Cancer, General Medicine, medicine.disease, Disease course, 03 medical and health sciences, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, medicine, 030212 general & internal medicine, business |
| الوصف: | Background: Cancer patients infected with SARS-CoV-2 during their active anticancer treatment represent a highly vulnerable population. We aimed this investigation to show clinical features and outcomes of the patients who had mild to moderate COVID-19 symptoms or were asymptomatic at the admission to the COVID Center. Patients and methods: The retrospective study included 25 cancer patients confirmed with SARS-CoV-2 within seven days of their last anticancer treatment. Clinical data were collected from medical records and processed by methods of descriptive and inferential statistics. Results: Patients’ mean age was 68.1±10.4 years. More than 2/3 of the patients were with ECOG PS 0 and 1, and about 4/5 of patients were in III or IV cancer stage. The most frequently applied types of therapy were radiotherapy and combined radio/chemotherapy. Eleven (44.0%) patients had bilateral while 4 (16%) had unilateral pneumonia. The most frequent symptoms were fever (72%), fatigue (72%), dyspnea (32%), and cough (32%). 1/5 of the patients needed oxygen support. Mean neutrophil (2.6±1.2), lymphocyte (0.9±0.6) and platelets (200.1±88.1) number significantly increased from admission to discharge (p=0.004, p=0.005, p Conclusion: Cancer patients infected with SARS-CoV-2 during active anticancer treatment can successfully overcome COVID-19 without developing further respiratory or other complications during hospitalization. An increase in lymphocyte and neutrophil counts, with a decrease in CRP, may be markers of a favorable prognosis. |
| تدمد: | 2335-075X 1820-8665 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_________::2b97e0fe0148e9d18a5ddb973cc5e792 https://doi.org/10.2478/sjecr-2020-0054 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi...........2b97e0fe0148e9d18a5ddb973cc5e792 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 2335075X 18208665 |
|---|